ライフサイエンスコーパス: antisense oligonucleotide

1 fter 4 weeks of treatment with the anti-Apob antisense oligonucleotide.

2 clinical study of intrathecal delivery of an antisense oligonucleotide.

3 g mouse hepatocytes by inhibiting it with an antisense oligonucleotide.

4 ed by targeting SRSF1 sites on exon 11 using antisense oligonucleotides.

5 m and validated their function in vivo using antisense oligonucleotides.

6 purposes using locked nucleic acid-modified antisense oligonucleotides.

7 interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides.

8 nted when CREB was depleted in these rats by antisense oligonucleotides.

9 tercalated anticancer drugs, and therapeutic antisense oligonucleotides.

10 n analyzed by knockdown using cell-permeable antisense oligonucleotides.

11 letion of TDP-43 from mouse adult brain with antisense oligonucleotides.

12 es are mainly induced by chemically modified antisense oligonucleotides.

13 CRISPR/Cas9 or by knocking down UBE3A using antisense oligonucleotides.

14 ical trials in patients treated with miR-122 antisense oligonucleotides.

15 iglyceride transfer protein inhibitor and an antisense oligonucleotide against APOB have recently bee

16 brain region in the learning, infusion of an antisense oligonucleotide against Arc into the shell imp

17 that Star:Star-mPEG mediated delivery of an antisense oligonucleotide against miR-145 (antimiR-145)

18 methyl-D-aspartate receptor antagonist or an antisense oligonucleotide against the activity-regulated

19 th/without the SIRT1 inhibitor nicotinamide, antisense oligonucleotides against SIRT1 (SIRT1-ASO), IL

20 r functional inhibition by sequence-specific antisense oligonucleotides allows the unprecedented telo

21 a mixed modality approach combining an Xist antisense oligonucleotide and a small-molecule inhibitor

22 Three participants who received the antisense oligonucleotide and three who received placebo

23 Coinjection of antisense oligonucleotides and DNA rescue constructs int

24 hip between in vivo inhibition of miR-182 by antisense oligonucleotides and improved post-injury kidn

25 The use of antisense oligonucleotides and other strategies to inter

26 Huntingtin-lowering strategies include antisense oligonucleotides and RNA interference targetin

27 ly important to design optimal sequences for antisense oligonucleotides and siRNA because both bind t

28 well as the effects of MCT blocker and MCT2 antisense oligonucleotides and siRNAs.

29 s an expected histologic change for a 2'-MOE antisense oligonucleotide, and no toxicity was attribute

30 tivity or expression with bromoenol lactone, antisense oligonucleotides, and genetic deletion, respec

31 ncrease SMN levels including drug compounds, antisense oligonucleotides, and scAAV9 gene therapy have

32 of short RNA or DNA segments such as siRNAs, antisense oligonucleotides, and transcription factor dec

33 Antisense oligonucleotides annealed appropriately 3' of

34 oss of contractile function, injection of an antisense oligonucleotide (antagomiR) against miR-25 mar

35 at silencing of brain-specific miR-134 using antisense oligonucleotides (antagomirs) had potent antis

36 out-of-frame DMD deletion can be repaired by antisense oligonucleotide (AO)-mediated exon skipping.

37 onic copolymer, cationic DOTAP liposome, and antisense oligonucleotide (AON).

38 PMLA, including a combination of morpholino antisense oligonucleotides (AON) directed against HER2/n

39 Antisense oligonucleotides (AON) were conjugated to the

40 Previously, we showed that naked antisense oligonucleotides (AONs) effectively restored n

41 Antisense oligonucleotides (AONs) hold promise for thera

42 Antisense oligonucleotides (AONs) were designed specific

43 Antisense oligonucleotides (AOs) are a promising DMD the

44 Nucleotide-based drug candidates such as antisense oligonucleotides, aptamers, immunoreceptor-act

45 Antisense oligonucleotides are not a new concept, but su

46 Antisense oligonucleotides are small, modified nucleic a

47 lly in areas of myofiber regeneration, where antisense oligonucleotides are stored in macrophages and

48 r" unit in a number of biologically relevant antisense oligonucleotides, are described using 5-methyl

49 Exon skipping uses antisense oligonucleotides as a treatment for genetic di

50 A specific antisense oligonucleotide (AS) effectively prevented cPL

51 This study sought to assess whether an antisense oligonucleotide (ASO) directed to apolipoprote

52 Systemically administered antisense oligonucleotide (ASO) inhibited miR-182 in the

53 ted with disease following treatment with an antisense oligonucleotide (ASO) targeted to the site of

54 another member of the contact system, using antisense oligonucleotide (ASO) technology results in an

55 We identified an exon 11 antisense oligonucleotide (ASO) that increased lamin C p

56 For this study, we compared a novel Gen 2 antisense oligonucleotide (ASO) that inhibits angiotensi

57 many as a half million components persist in antisense oligonucleotide (ASO) therapeutics because it

58 Antisense oligonucleotide (ASO) therapeutics show tremen

59 nfirmed in ALS brain and were mitigated with antisense oligonucleotide (ASO) therapeutics to the C9OR

60 siewicz et al. show the benefit of transient antisense oligonucleotide (ASO) therapy to degrade Hunti

61 a loss-of-function approach using a specific antisense oligonucleotide (ASO) to decrease expression p

62 d for 4 wk with a 2'-O-methoxyethyl chimeric antisense oligonucleotide (ASO) to decrease hepatic and

63 We utilize an antisense oligonucleotide (ASO) to reduce apoE expressio

64 CGI-58 knockdown in mice using antisense oligonucleotide (ASO) treatment also leads to

65 pivotal proof of principle that therapeutic antisense oligonucleotide (ASO) treatment can effectivel

66 An antisense oligonucleotide (ASO) was used to correct defe

67 We used an antisense oligonucleotide (ASO), ASO-10-27, that effecti

68 protein inhibitor (MTPI), and mipomersen, an antisense oligonucleotide (ASO), have been shown to impr

69 We used an antisense oligonucleotide (ASO)-based inducible mouse mo

70 rebroventricular insulin and leptin, and Tub antisense oligonucleotide (ASO).

71 We have previously reported on an antisense oligonucleotide (ASO-29) that dramatically imp

72 mine whether down-regulation of Sirt-1 using antisense oligonucleotides (ASO) affects inflammatory an

73 Antisense oligonucleotides (ASO) blocking MALAT1 prevent

74 The in vivo potency of antisense oligonucleotides (ASO) has been significantly

75 t of diet-induce obese (DIO) mice with FGFR4 antisense oligonucleotides (ASO) specifically reduced li

76 Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the

77 cer therapy, we here report the synthesis of antisense-oligonucleotides (ASO) and thyroid hormone T3

78 nces the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6-10-fold in mouse liv

79 gene-specific method of NMD inhibition using antisense oligonucleotides (ASOs) and combine this appro

80 hods to suppress expression of mRNAs include antisense oligonucleotides (ASOs) and RNA interference (

81 Antisense oligonucleotides (ASOs) and RNA-interference a

82 or toxicity contribute to the limited use of antisense oligonucleotides (ASOs) and siRNA as therapeut

83 Antisense oligonucleotides (ASOs) are an established too

84 RNase H1-dependent antisense oligonucleotides (ASOs) are chemically modifie

85 ly mitigated through chemical modifications, antisense oligonucleotides (ASOs) are gaining recognitio

86 Antisense oligonucleotides (ASOs) are identified that re

87 Antisense oligonucleotides (ASOs) are known to trigger m

88 Antisense oligonucleotides (ASOs) are most commonly desi

89 Antisense oligonucleotides (ASOs) are often used to down

90 Antisense oligonucleotides (ASOs) are recognized therape

91 Antisense oligonucleotides (ASOs) are small sequences of

92 Antisense oligonucleotides (ASOs) are synthetic oligonuc

93 Antisense oligonucleotides (ASOs) are versatile molecule

94 Antisense oligonucleotides (ASOs) are versatile tools th

95 Here, we report the use of antisense oligonucleotides (ASOs) as a therapeutic appro

96 hat administering systemically SMN-restoring antisense oligonucleotides (ASOs) at the age of onset ca

97 fected 20-mer phosphorothioate-modified (PS) antisense oligonucleotides (ASOs) can recruit paraspeckl

98 High affinity antisense oligonucleotides (ASOs) containing bicylic mod

99 The ability to control gene expression with antisense oligonucleotides (ASOs) could provide a new tr

100 Chemically modified antisense oligonucleotides (ASOs) designed to mediate si

101 Antisense oligonucleotides (ASOs) designed to serve as s

102 Here, we show that antisense oligonucleotides (ASOs) effectively suppress P

103 DNA-based antisense oligonucleotides (ASOs) elicit cleavage of the

104 Here, we found that treating mice with apoB antisense oligonucleotides (ASOs) for 6 weeks decreased

105 Antisense oligonucleotides (ASOs) for ApoC-III reduce pl

106 imary hepatocytes, whereas transfection with antisense oligonucleotides (AsOs) for miR-103/miR-107 in

107 on of gene expression by chemically modified antisense oligonucleotides (ASOs) has been well characte

108 Phosphorothioate (PS)-modified antisense oligonucleotides (ASOs) have been extensively

109 Phosphorothioate (PS) antisense oligonucleotides (ASOs) have been successfully

110 Antisense oligonucleotides (ASOs) hold promise for gene-

111 etermined whether decreasing TTR levels with antisense oligonucleotides (ASOs) improves glucose metab

112 ate (PS)-modified tricycloDNA (tcDNA) gapmer antisense oligonucleotides (ASOs) in T(m), cell culture

113 c loss or systemic knockdown of Malat1 using antisense oligonucleotides (ASOs) in the MMTV (mouse mam

114 Targeted degradation of SMN-AS1 with antisense oligonucleotides (ASOs) increases SMN expressi

115 Here we show that systemic delivery of Dnm2 antisense oligonucleotides (ASOs) into Mtm1KO mice effic

116 Antisense oligonucleotides (ASOs) modified with phosphor

117 RNase H active antisense oligonucleotides (ASOs) or small interfering R

118 educed expression of Thrap3 in fat tissue by antisense oligonucleotides (ASOs) regulates a specific s

119 s study, we used gene therapy in the form of antisense oligonucleotides (ASOs) specifically to silenc

120 Antisense oligonucleotides (ASOs) targeted to the CAG re

121 We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 mess

122 We identified second generation antisense oligonucleotides (ASOs) targeting mouse Tmprss

123 Selective second-generation antisense oligonucleotides (ASOs) targeting Sulf2 were i

124 With antisense oligonucleotides (ASOs) that catalyze RNase H-

125 Single-dose injection of antisense oligonucleotides (ASOs) that target repeat-con

126 y showed that translation can be enhanced by antisense oligonucleotides (ASOs) that target upstream o

127 The available strategies include the use of antisense oligonucleotides (ASOs) to alter splicing or k

128 Exon skipping uses antisense oligonucleotides (ASOs) to alter transcript sp

129 Mice were injected with antisense oligonucleotides (ASOs) to knockdown Mogat1 or

130 ng approach to treat DM1 uses DMPK-targeting antisense oligonucleotides (ASOs) to reduce levels of to

131 this issue of the JCI, successfully utilized antisense oligonucleotides (ASOs) to reduce PMP22 and am

132 or extrinsic pathway of coagulation, we used antisense oligonucleotides (ASOs) to selectively knock d

133 ies of phosphorothioate (PS)-modified gapmer antisense oligonucleotides (ASOs) with control of the ch

134 Fully phosphorothioate antisense oligonucleotides (ASOs) with locked nucleic ac

135 Antisense oligonucleotides (ASOs) with phosphorothioate

136 ll-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic m

137 In this study, using splice-switching antisense oligonucleotides (ASOs), we increased the synt

138 Angelman syndrome by reducing Ube3a-ATS with antisense oligonucleotides (ASOs).

139 directed at the ATXN2 gene by screening 152 antisense oligonucleotides (ASOs).

140 otide strategies to silence gene expression, antisense oligonucleotide-based cancer therapy has not b

141 eutics and more than 100 clinical trials for antisense oligonucleotide-based technologies; in fact, t

142 In just the past 5 years, over 100 antisense oligonucleotide-based therapies have been test

143 Using a morpholino-antisense-oligonucleotide-based zebrafish model for CHAR

144 enced in gluconeogenic tissues of rats using antisense oligonucleotides both in vivo and in isolated

145 ve shown that a locked nucleic acid-modified antisense oligonucleotide complementary to the CAG repea

146 whether cenersen, a clinically active 20-mer antisense oligonucleotide complementary to TP53 exon10,

147 Inhibition of CEACAM20 with antisense oligonucleotides completely inhibited tubule f

148 Knockdown of hepatic VEGF with antisense oligonucleotides completely prevented dimethyl

149 , we utilized very short chemically modified antisense oligonucleotides composed exclusively of locke

150 tion of the binding domain or treatment with antisense oligonucleotides compromises Musashi function.

151 bilization of pausing, were competitive with antisense oligonucleotide concentration, suggesting that

152 itionally, systemic treatment with a peptide-antisense oligonucleotide conjugate designed to induce D

153 with pre-existing dystrophic pathology using antisense oligonucleotides conjugated to a cell-penetrat

154 Antisense oligonucleotides delivered to the CNS might be

155 ly studied polyplex size range for siRNA and antisense oligonucleotide delivery applications.

156 We present an untemplated, single-component antisense oligonucleotide delivery system capable of reg

157 ect of IONIS-APO(a)-LRx, a ligand-conjugated antisense oligonucleotide designed to be highly and sele

158 cacy, safety, and tolerability of two unique antisense oligonucleotides designed to lower Lp(a) conce

159 We used an antisense oligonucleotide directed against CRTC2 in both

160 Nusinersen is an antisense oligonucleotide drug that modifies pre-messeng

161 d elements involved in mRNA processing using antisense oligonucleotide drugs can be used as a strateg

162 stream of SMN2 exon 7 using Morpholino-based antisense oligonucleotides (E1(MO)-ASOs).

163 tion site in ARIH2 3' untranslated region by antisense oligonucleotides elevates the expression of AR

164 o its first human clinical trial, with other antisense oligonucleotides expected to enter trials in t

165 We still do not have a marketed antisense oligonucleotide for a cancer indication.

166 Weekly administration of FII antisense oligonucleotide "gapmer" to Berkeley SCD mice

167 drisapersen, a 2'-O-methyl-phosphorothioate antisense oligonucleotide, given for 48 weeks.

168 e show that acute depletion of Platr14 using antisense oligonucleotides impacts the differentiation-

169 uently, down-regulation of PDI expression by antisense oligonucleotides impaired the spreading of cel

170 e GSK126, or decreasing its expression using antisense oligonucleotides, impeded osteoclast different

171 3 decoy (Ad.decoymiR-503) or by antimiR-503 (antisense oligonucleotide) improved the functional capac

172 38alpha protein was reversed by miR-124/-128 antisense oligonucleotides in primary explant neuronal c

173 ntracerebroventricular administration of the antisense oligonucleotides in the presymptomatic phase e

174 hermore, delayed administration of periostin antisense oligonucleotides in wild-type animals with GN

175 Antisense oligonucleotide-induced loss of HMGCS2 in chow

176 Antisense-oligonucleotide-induced exon skipping allows s

177 EACAM1 with antibodies or soluble CEACAM1 or antisense oligonucleotides inhibited tubule formation by

178 U1-70K knockdown or antisense oligonucleotide inhibition of U1 snRNP increas

179 Mipomersen, an antisense oligonucleotide inhibitor of apolipoprotein B,

180 of ISIS 416858, a 2'-methoxyethoxy (2'-MOE) antisense oligonucleotide inhibitor of FXI, with focus o

181 iated delivery of phosphorothioated TRAF3IP2 antisense oligonucleotides into the LV in a clinically r

182 model of amyotrophic lateral sclerosis, the antisense oligonucleotide ISIS 333611 delivered to CSF d

183 Antisense oligonucleotide knockdown of hepatic ASS1 expr

184 Antisense oligonucleotide knockdown of hepatic mitochond

185 In contrast, antisense oligonucleotide knockdown of HTT in WT co-cult

186 PSC-derived human cortical neurons following antisense oligonucleotide knockdown.

187 Knockdown of either gene by morpholino antisense oligonucleotides leads to profound defects in

188 Antisense oligonucleotides linked by phosphorothioates a

189 onceptus, we conducted an in vivo morpholino antisense oligonucleotide (MAO)-mediated knockdown of SL

190 Antisense oligonucleotides may be coupled to high-affini

191 atient-derived xenograft (PDX) mouse models, antisense oligonucleotide-mediated (ASO-mediated) skippi

192 However, antisense oligonucleotide-mediated exon skipping for DMD

193 geting mast cells in vitro and in vivo using antisense oligonucleotide-mediated exon skipping of the

194 (1) restoration of dystrophin expression by antisense oligonucleotide-mediated exon-skipping in mdx

195 renia-related lncRNA was explored in vivo by antisense oligonucleotide-mediated gene knockdown in the

196 Here we report that in zebrafish, morpholino antisense oligonucleotide-mediated knockdown of PCP gene

197 Antisense oligonucleotide-mediated knockdown of SPAK, an

198 binding sites based on insensitivity to DNA antisense oligonucleotide-mediated RNase H digestion.

199 We show that an antisense oligonucleotide-mediated sequestration of the

200 d the repertoire of potential targets for an antisense oligonucleotide-mediated therapy of SMA.

201 pies such as mipomersen, a second-generation antisense oligonucleotide, microsomal triglyceride trans

202 ort new insights into these mechanisms using antisense oligonucleotide mimics of a pause RNA hairpin

203 using the locked nucleic acid (LNA)-modified antisense oligonucleotide miravirsen.

204 Antisense oligonucleotides, miRNA sponges, and CRISPR/Ca

205 phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and

206 Transient transfection of MSCs with SIRT1-antisense oligonucleotides, nicotinamide, and IL-1beta i

207 ects of reducing expression, with morpholino antisense oligonucleotides, on biliary development, gene

208 isense oligonucleotide or a mismatch control antisense oligonucleotide once a week for 1 or 4 weeks b

209 Sepsis with cotreatment of antibiotics and antisense oligonucleotides (one against secretory phosph

210 Several RNA-targeted therapeutics, including antisense oligonucleotides (ONs), small interfering RNAs

211 lly manipulated CD46 exon 13 inclusion using antisense oligonucleotides, opening up opportunities for

212 t mice were treated with either an anti-Apob antisense oligonucleotide or a mismatch control antisens

213 Either NPR-C inhibition by antisense oligonucleotide or NPR-C gene silencing by sma

214 of myoblasts, while inhibition of miR-26a by antisense oligonucleotides or by Tough-Decoys delays dif

215 Knock-down of InsP3R1 expression by antisense oligonucleotides or knock-down or knock-out of

216 the RNA-binding protein Nanos2 by morpholino antisense oligonucleotides, or knockout of the Nanos2 ge

217 scular dystrophy (DMD), employing morpholino antisense oligonucleotides (PMO-AO) to exclude disruptiv

218 ntronic splicing enhancer using a Morpholino antisense oligonucleotide prevented B19V mRNA transcript

219 lly, miR-29b blockade by locked nucleic acid antisense oligonucleotides prevented early aneurysm deve

220 Eye drops of aganirsen, an antisense oligonucleotide preventing insulin receptor su

221 Tyk2, or their downstream target 15-LO with antisense oligonucleotides profoundly inhibits IL-13-ind

222 Knockdown of miR-29a by antisense oligonucleotides promoted HDAC4 action, nephri

223 The anti-Apob antisense oligonucleotide reduced plasma cholesterol by

224 ability in adult animals and suggest that an antisense oligonucleotide reduction of tau could benefit

225 Targeting tRNA(Arg)(UCU) with an antisense oligonucleotide replicated effects of Hili and

226 vascular delivery of bromoenol lactone or of antisense oligonucleotides, respectively.

227 Moreover, the incorporation of therapeutic antisense oligonucleotides resulted in the inhibition of

228 pinocerebellar ataxias, including the use of antisense oligonucleotides, short-interfering RNAs, as w

229 etion of key proteins of the RISC pathway by antisense oligonucleotides significantly impairs pre-rRN

230 CSK9 synthesis in the endoplasmic reticulum (antisense oligonucleotides, siRNAs), and interfere with

231 Injection of morpholino (MO)-modified antisense oligonucleotides specifically designed to knoc

232 Single-stranded antisense oligonucleotides (SSOs) are used to modulate t

233 whether promoted by stem-loop, pseudoknot or antisense oligonucleotide stimulator.

234 frameshifting with stem-loop, pseudoknot or antisense oligonucleotide stimulators.

235 We also reduced MeCP2 using an antisense oligonucleotide strategy, which has greater tr

236 ockdown of total alpha-synuclein with potent antisense oligonucleotides substantially reduces inclusi

237 dy, we systemically treated PiZ mice with an antisense oligonucleotide targeted against hAAT (AAT-ASO

238 We show that modified antisense oligonucleotides targeted to a splicing enhanc

239 ction can be achieved by exon skipping using antisense oligonucleotides targeted to splicing elements

240 ive subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA in a si

241 pendent clinical trials with drisapersen, an antisense oligonucleotide targeting exon 51: an open lab

242 Antisense oligonucleotides targeting Alu/B1/B2 RNAs prev

243 Antisense oligonucleotides targeting C9orf72 have shown

244 nslated dipeptides, which were suppressed by antisense oligonucleotides targeting human C9orf72.

245 Antisense oligonucleotides targeting human SOD1 were adm

246 We further showed that antisense oligonucleotides targeting the SF2 binding sit

247 Antisense oligonucleotide technology targeting the commo

248 An intrathecally delivered antisense oligonucleotide that aims to lower huntingtin

249 We generated a C6 antisense oligonucleotide that blocks MAC formation by i

250 Custirsen is a second-generation antisense oligonucleotide that inhibits clusterin produc

251 X011) is a second generation highly specific antisense oligonucleotide that inhibits the production o

252 d nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122

253 FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces fact

254 rthermore, EZN-3920, a chemically stabilized antisense oligonucleotide that targets the ErbB3 mRNA in

255 The only approved SMA treatment is an antisense oligonucleotide that targets the intronic spli

256 n blood vessels were treated with morpholino antisense oligonucleotides that blocked the expression o

257 In contrast, similarly targeted MOE-gapmer antisense oligonucleotides that degrade RNA but do not e

258 peptide-phosphorodiamidate morpholino (PPMO) antisense oligonucleotides that induced temporary dystro

259 uo et al. demonstrate that administration of antisense oligonucleotides that reduce expression of Tmp

260 lity profile in adult animals, we identified antisense oligonucleotides that selectively decrease end

261 The development of antisense oligonucleotide therapy is an important advanc

262 c marker for SOD1-lowering therapies because antisense oligonucleotide therapy lowers protein levels

263 Antisense oligonucleotides thus represent a promising th

264 models using a therapeutic splice-switching antisense oligonucleotide to restore SMN and a complemen

265 n B-100 (apoB) containing lipoproteins, with antisense oligonucleotides to apoB, monoclonal antibodie

266 Using antisense oligonucleotides to block the activity of a sp

267 he contact system, we used DNase, RNase, and antisense oligonucleotides to characterize the FeCl3 mod

268 s we treated high-fat-fed rats with specific antisense oligonucleotides to decrease hepatic and adipo

269 d on a modular hybrid minigene combined with antisense oligonucleotides to enable verification of fun

270 In vivo delivery of antisense oligonucleotides to inhibit periostin expressi

271 Here, we exploited synthetic antisense oligonucleotides to inhibit the RNA levels of

272 We used Cavbeta antisense oligonucleotides to knock down Cavbeta and gab

273 istration of a proteasomal inhibitor or CHIP antisense oligonucleotides to knock down CHIP reversed t

274 We used antisense oligonucleotides to knock down Lxralpha in mic

275 cts was assessed in transgenic mice by using antisense oligonucleotides to reduce levels of toxic RNA

276 We used antisense oligonucleotides to reduce SirT1 to levels sim

277 al aggression in songbirds, and thus we used antisense oligonucleotides to selectively block AH VIP p

278 Using antisense oligonucleotides to shift PKM splicing toward

279 time window of response to administration of antisense oligonucleotides to SMA mice with an intermedi

280 eases, might be pursued as an alternative to antisense oligonucleotides to target structured RNAs of

281 et patients with specific mutations, such as antisense oligonucleotides, to induce exon skipping of s

282 uppressing MdMYB39L expression in pollen via antisense oligonucleotide transfection significantly red

283 ced hepatic insulin resistance in both TLR-4 antisense oligonucleotide treated and TLR-4 knockout mic

284 insulin receptor 2'-O-methoxyethyl chimeric antisense oligonucleotide-treated rats.

285 Antisense oligonucleotide-treated SOD1G93A rats had decr

286 t the combinatorial effect of suboptimal SMN antisense oligonucleotide treatment and PLS3 overexpress

287 Antisense oligonucleotide treatment caused dose-responsi

288 We find that antisense oligonucleotide treatment induces a broad phen

289 Additionally, antisense oligonucleotide treatment markedly decreased l

290 The antisense oligonucleotides used for exon skipping are de

291 no-5-phosphonopentanoic acid (AP5) or an Arc antisense oligonucleotide was infused into the DM striat

292 Using antisense oligonucleotides we demonstrated that disrupti

293 loying heat-inducible transgenic strains and antisense oligonucleotides, we demonstrate that decrease

294 In sepsis rats, antisense oligonucleotides were capable of reducing thei

295 Antisense oligonucleotides were designed based on the se

296 Rodent- and human-specific second-generation antisense oligonucleotides were identified and evaluated

297 Both antisense oligonucleotides were safe.

298 When C9ORF72 was overexpressed or antisense oligonucleotides were targeted to the C9orf72

299 simplicity and favorable biodistribution of antisense oligonucleotides with robust silencing through

300 ld combine the simplicity of single-stranded antisense oligonucleotides with the efficiency of RNAi.